The Potassium and Metabolic Alkalosis lecture:
The Acid Base Lecture
The Potassium lecture (on your own)
The Sodium and Water Handout
The Electrolyte and Acid Base Companion
Of all the concepts in fluids and electrolytes by far the most difficult is sodium, water and volume regulation. I think the problems stem from multiple angles, one of which is the confusion between total body sodium (reflected in volume status) and sodium concentration (the primary determinant of osmolality). When writing the sodium chapters I kept thinking about that exchange on Dagobah:
Good Afternoon Dr. Topf,
I am a student at OUWB and you ran our TBL this past week. I’ve been struggling with this material and I was previewing for lectures next week. I apologize for emailing over the weekend, but I am confused over a concept that we went over in TBL – that is, the impetus for release/action of the RAAS system and ADH.
From our discussion and our physiology class prior in the week, I am understanding that ADH primarily regulates osmolarity and that aldosterone primarily regulates blood volume. However, it seems that as I go over review books, I’m being told that ADH, “…also responds to low blood volume, which takes precedence over osmolarity,” (First Aid), and from our physiology text book (Costanzo), it indicates that ADH has 3 functions including:
1. increasing H2O permeability of principal cells (which the text indicates is the primary function)
2. increasing activity of the Na+/K+/2Cl- cotransporter
3. increases urea permeability
Upon my own research, a neuroscience text book source (from the University of Texas) indicates that there are angiotensin II receptors located in the subfornical organ which, upon binding of angiotensin II, cause a release of ADH from the posterior pituitary. I feel like I’m getting different information on what ADH’s role is a response to.
In the case of isotonic volume loss (eg. hemorrhage, diarrhea), you would get activation of the RAAS system as a response to low blood volume/BP. My confusion rests in – does ADH get released as a result solely of the volume loss (not in response to a change in osmolarity) via the angiotensin II – subfornical organ – posterior pituitary pathway? (implying its importance and precedence in preserving blood volume over osmolarity?)
OR is the production of aldosterone in this situation which leads to increased Na+ absorption, which in turn increases blood osmolarity leading to ADH release the mechanism for ADH release in relation to preservation of blood volume?
Thank you kindly in advance.
Best,
[Name withheld]
Sources: Physiology 4th ed. Linda S Costanzo pg. 291
First Aid for the USMLE Step-1 2013 Tao Le, Vikas Bhushan pg. 485
http://neuroscience.uth.tmc.edu/s4/chapter02.html Patrick Dougherty, Ph.D
Here was my reply
[Name withheld],
The goal of medical physiology is to build a model of how the body works so that the student can predict how the body will respond to various inputs. The more advanced the model the more situations the model will accurately predict the outcomes. Of course the down side of the more complex model is it becomes more and more difficult to remember and keep accessible for use.
Every concept in physiology that is taught should be taught as a step in building an accurate model. Any student that tries to memorize the avalanche of physiology facts without fitting them into a model will be lost. Additionally, students that confuse the model for reality will be disappointed because no model can adequately describe the wonderful complexity of the human body. The sweet spot is adopting a model that is accurate enough to describe the clinical scenarios you encounter in medicine without being so complex to confuse the user
This is especially appropriate for renal physiology.
Short answer is you have it right.:
RAAS is for volume (BP and perfusion) regulation and ADH is for osmoregulation.
Additionally the statement that ADH also responds to volume is also correct and essential in understanding why heart failure and volume depletion leads to hyponatremia. In both CHF and hyponatremia the perfusion is compromised so much that ADH is released (not because of high osmolality but because of the low perfusion signal for ADH). This ADH concentrates the urine and lowers urine output. Then even modest amounts of water will exceed intake and sodium is diluted.
The additional statement that it takes precedence over osmolality is critical. When there is simultaneous low osmolality (suppresses ADH) and low blood pressure (stimulates ADH), the volume stimulus wins. In the hierarchy of need, maintaining perfusion takes precedence over osmoregulation.
a page from the best book I ever wrote |
Regarding Costanzo’s three functions:
If you believe this is an important function of ADH you will assume that SIADH, a condition of unregulated over production of ADH will cause sodium accumulation (due to stimulation fo NaK2Cl pump) when in reality the most important aspect of SIADH to understand is that SIADH is a sodium neutral state (sodium in = sodium out) and only causes hyponatremia due to the over reabsorption of water (due to the ADH)
In regards to the neuroscience textbook indicting AT2 receptors as a critical signal for ADH release. This is likely the trigger for the volume dependent release of ADH we discussed above. But again this is a fact that can be safely ignored because if you focus on AT2’s role in ADH release you may falsely assume that ACE inhibitors (and angiotensin receptor blockers and renin blockers) will block these receptors, decrease ADH and cause a diabetes insipidus picture. This does not happen. Keep it simple.
Your final question is about isotonic volume loss, the answer is: you are clearly describing a perfusion related release of ADH. Do not use an overly complex Rube Goldberg system of increasing osmolality to release ADH.
I also would recommend my book. You can download the whole thing for free (PDF). It is long and Adobe Acrobat did a shitty job of rendering much of the text but it is excellent and it is free.
1 tsp salt = 2,300mg sodium = 100 mmol sodium
@kidney_boy Your math is correct, of course depending on the size of a table spoon http://t.co/OvkVzDoWMJ. In netherlands 1tsp = 10g NaCl
— Martijn vd Hoogen (@MWF_vd_Hoogen) August 13, 2014
@kidney_boy would be good to say glucose instead of “sugar”
— Lewis (@Lewis_Lab) August 14, 2014
We had a patient, who had been healthy until he ran into some a-fib. He then began a months long descent into the depths of decompensated heart failure. His dry weight prior to decompensation was 208. On admission to the hospital he was 262.
It took over a month of acute and sub-acute care, a failed cardioversion, a pacer, and a cardiac ablation, but he ultimately emerged from his heart failure. He is now back to his dry weight. He went from 208 to 262 pounds to 208 pounds’ That is 54 pounds of water weight. My understanding of heart failure is this excess fluid is almost entirely extracellular.
Think about how much water and sodium that is:
“What Color Is Your Pee?” #medical #humor #medicine pic.twitter.com/iMhJdLgShu
— Dr. Bradford Holland (@DrBradHolland) July 11, 2014
Here is the potassium lecture in all its glory.
If you want to know more about why I allow people to download an editable version of the lecture read this.
The videos are here:
I can’t post to Vimeo until next week. So google docs once again.
The hypokalemima section did not cover vomiting, so I added this addendum.
Part 3 is uploading right now so the final pots with all three parts and the keynote and PDF will be available tonight.
For decades we have known that membranous nephropathy was an antibody induced glomerulonephritis, we just didn’t know what the antigen was. Then, in 2009, Beck et al. rocked nephrology by discovering the antigen, Phospholipase A2 antibodies were detracted in 70% of patients with membranous nephropathy and no patients with either secondary membranous, other proteinuric glomerulonephritis or normal controls. Since then there has been a steady stream of positive trials showing tight association with aPLA2R antibodies and disease activity in idiopathic membranous nephropathy.
This month both CJSAN’s eJC and #NephJC will be going deep with studies that examine the state of the art in aPLA2R research.
This month CJASN’s online journal club is doing an interesting article looking at aPLA2R status at the beginning and end of therapy and its ability to predict long-term outcomes. It is a unique study with multiple titers of aPLA2r over the course of time matched with 5 years of follow-up. Though it is not the biggest trial of aPLA2R in some ways it is the best and it is an important step in understanding how to use this new tool in the management of membranous nephropathy.
Every month eJC has a sponsor, this month that sponsor is my home institution St John Hospital and Medical Center in Detroit. My fellow and I reviewed most of the key studies in aPLA2r and provided a helpful summary of this study. Check out our background post at Medium and then participate in the forum.
#NephJC will be shortly announcing its article for discussion and then have a twitter discussion on August 12th at 9pm EDT.
Once agin I have the honor of teaching the second year medical students at Oakland University William Beaumont School of Medicine. I have 4 points of contact with the students: